CN106509890A - 一种缓解女性更年期综合症的组合物及其制备方法 - Google Patents
一种缓解女性更年期综合症的组合物及其制备方法 Download PDFInfo
- Publication number
- CN106509890A CN106509890A CN201610966018.6A CN201610966018A CN106509890A CN 106509890 A CN106509890 A CN 106509890A CN 201610966018 A CN201610966018 A CN 201610966018A CN 106509890 A CN106509890 A CN 106509890A
- Authority
- CN
- China
- Prior art keywords
- oil
- parts
- vitamin
- preparation
- compositionss
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 208000011580 syndromic disease Diseases 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims description 12
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims abstract description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 235000008696 isoflavones Nutrition 0.000 claims abstract description 14
- 244000068988 Glycine max Species 0.000 claims abstract description 13
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 13
- 239000003085 diluting agent Substances 0.000 claims abstract description 9
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 9
- 239000011707 mineral Substances 0.000 claims abstract description 9
- 229930003231 vitamin Natural products 0.000 claims abstract description 8
- 235000013343 vitamin Nutrition 0.000 claims abstract description 8
- 239000011782 vitamin Substances 0.000 claims abstract description 8
- 229940088594 vitamin Drugs 0.000 claims abstract description 8
- 239000007901 soft capsule Substances 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 30
- 239000002775 capsule Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 239000003921 oil Substances 0.000 claims description 15
- 235000019198 oils Nutrition 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000010681 turmeric oil Substances 0.000 claims description 11
- 229940106134 krill oil Drugs 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- 235000010755 mineral Nutrition 0.000 claims description 7
- 239000000049 pigment Substances 0.000 claims description 7
- 239000003292 glue Substances 0.000 claims description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000000465 moulding Methods 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims description 4
- 229930003270 Vitamin B Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 235000010216 calcium carbonate Nutrition 0.000 claims description 4
- -1 ferrous porphyrin Chemical class 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 238000009413 insulation Methods 0.000 claims description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 claims description 4
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 claims description 4
- 239000011720 vitamin B Substances 0.000 claims description 4
- 235000019156 vitamin B Nutrition 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011670 zinc gluconate Substances 0.000 claims description 3
- 235000011478 zinc gluconate Nutrition 0.000 claims description 3
- 229960000306 zinc gluconate Drugs 0.000 claims description 3
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 2
- DKKCQDROTDCQOR-UHFFFAOYSA-L Ferrous lactate Chemical compound [Fe+2].CC(O)C([O-])=O.CC(O)C([O-])=O DKKCQDROTDCQOR-UHFFFAOYSA-L 0.000 claims description 2
- 229930003268 Vitamin C Natural products 0.000 claims description 2
- 239000010495 camellia oil Substances 0.000 claims description 2
- 235000012730 carminic acid Nutrition 0.000 claims description 2
- 238000004040 coloring Methods 0.000 claims description 2
- 235000013925 ferrous lactate Nutrition 0.000 claims description 2
- 239000004225 ferrous lactate Substances 0.000 claims description 2
- 229940037907 ferrous lactate Drugs 0.000 claims description 2
- 230000014759 maintenance of location Effects 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 235000005713 safflower oil Nutrition 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000004408 titanium dioxide Substances 0.000 claims description 2
- 235000019154 vitamin C Nutrition 0.000 claims description 2
- 239000011718 vitamin C Substances 0.000 claims description 2
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 2
- 229960001763 zinc sulfate Drugs 0.000 claims description 2
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 2
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 1
- 235000011149 sulphuric acid Nutrition 0.000 claims 1
- 239000001117 sulphuric acid Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 238000000034 method Methods 0.000 abstract description 4
- 241000407170 Curcuma Species 0.000 abstract 2
- 235000014375 Curcuma Nutrition 0.000 abstract 2
- 241000239370 Euphausia superba Species 0.000 abstract 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 2
- 238000013329 compounding Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000005453 pelletization Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229940088597 hormone Drugs 0.000 description 7
- 239000005556 hormone Substances 0.000 description 7
- 239000003814 drug Substances 0.000 description 5
- 206010060800 Hot flush Diseases 0.000 description 4
- 230000009245 menopause Effects 0.000 description 4
- 241000239366 Euphausiacea Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 229930003316 Vitamin D Natural products 0.000 description 3
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 3
- 230000003110 anti-inflammatory effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002124 endocrine Effects 0.000 description 3
- 229940011871 estrogen Drugs 0.000 description 3
- 239000000262 estrogen Substances 0.000 description 3
- 230000003054 hormonal effect Effects 0.000 description 3
- 210000001672 ovary Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000011710 vitamin D Substances 0.000 description 3
- 235000019166 vitamin D Nutrition 0.000 description 3
- 150000003710 vitamin D derivatives Chemical class 0.000 description 3
- 229940046008 vitamin d Drugs 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 2
- 102000009151 Luteinizing Hormone Human genes 0.000 description 2
- 108010073521 Luteinizing Hormone Proteins 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- CHZJRGNDJLJLAW-RIQJQHKOSA-N (8r,9s,13s,14s,16r,17r)-3-cyclopentyloxy-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthrene-16,17-diol Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1C[C@@H](O)[C@@]4(O)C#C)C)CC2=CC=3OC1CCCC1 CHZJRGNDJLJLAW-RIQJQHKOSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 208000012287 Prolapse Diseases 0.000 description 1
- 206010056610 Pseudoangina Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010046814 Uterine prolapse Diseases 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001781 ferrous sulfate Drugs 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000002149 gonad Anatomy 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 229950007863 nilestriol Drugs 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 229940012843 omega-3 fatty acid Drugs 0.000 description 1
- 239000006014 omega-3 oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 108010048734 sclerotin Proteins 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/612—Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Insects & Arthropods (AREA)
- Marine Sciences & Fisheries (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种缓解女性更年期综合症的组合物,按重量份计,包括如下组分:大豆异黄酮5‑20份、南极磷虾油5‑20份、姜黄油5‑20份、稀释剂30‑50份、维生素1‑5份、矿物质1‑5份,本发明通过大豆异黄酮、南极磷虾油、姜黄油、稀释剂、维生素和矿物质进行复配,并通过制丸技术,获得的软胶囊组合物产品对缓解女性更年期综合症方面具有很好的效果,且效果显著,无其它副作用。
Description
技术领域
本发明涉及一种食品组合物,尤其涉及一种缓解女性更年期综合症的组合物,属于保健食品技术加工领域。
背景技术
“更年期”常被用于指绝经过渡期。绝经后一般指的是卵巢内卵泡耗竭后的自然绝经状态,或是剩余卵泡对促性腺激素反应降低甚至消失的状态。这一时期卵泡发育和雌激素分泌停止,激素无法剌激子宫内膜生长,最后出现绝经。更年期的平均年龄为50岁,开始和结束的时间因地域、环境、种族和个人情况而异。更年期主要症状有四种:①自主神经系统功能紊乱伴有神经心理症状的症候群;②泌尿生殖道症状,可出现外阴及阴道萎缩;膀胱及尿道的症状;子宫脱垂及阴道壁膨出;③心血管症状部分,患者有假性心绞痛,有时伴心悸、胸闷。少数患者出现轻度高血压,特点为收缩压升高、舒张压不高,阵发性发作,血压升高时出现头昏、头痛、胸闷、心悸。④骨质疏松妇女从围绝经期开始,骨质吸收速度大于骨质生成,促使骨质丢失而骨质疏松。
更年期属于人类正常生理阶段,并不需要药物治疗。但更年期阶段内分泌变化引起的神经性或精神状况的紊乱需要进行适当的药物干预。除了适当的心理咨询及物理治疗(如针灸、按摩)外,临床多采用类固醇类激素、抗抑郁药、降压药、镇静催眠药等药物治疗的方法来缓解更年期阶段出现的各种症状。这些药物大多是西药治疗,虽然部分缓解症状,但由于药物的长期服用产生毒副作用,增加了患者的疑虑,使临床应用受到严格限制。
发明内容
本发明针对现有缓解更年期症状药物存在的不足,提供一种缓解女性更年期综合症的组合物及其制备方法。
本发明解决上述技术问题的技术方案如下:
一种缓解女性更年期综合症的组合物,其特征在于,按重量份计,包括如下组分:大豆异黄酮5-20份、南极磷虾油5-20份、姜黄油5-20份、稀释剂30-50份、维生素1-5份、矿物质1-5份。
进一步,所述稀释剂为亚麻籽油、红花油、月见草油、山茶油、米糠油、玉米油中的一种或多种的混合物。
进一步,所述维生素为维生素E、维生素C、维生素D、B族维生素中的一种或多种的混合物。
进一步,所述矿物质为葡萄糖酸锌、硫酸锌、硫酸亚铁、卟啉铁、乳酸亚铁、碳酸钙的一种或多种的混合物。
本配方的药理及功效总结如下:
1、补充天然雌激素,改善内分泌,大豆异黄酮与女性体内的雌激素相似,具有改善内分泌的作用,可改善激素下降引起的更年期症状。
2、调节激素调节:南极磷虾油富含OMEGA-3不饱和脂肪酸,可调节卵巢内激素分泌量,同时还有消炎、止痛的作用,从而减轻更年期痛症的现象。含有特别丰富的磷脂(大约38%),能将OMEGA-3脂肪酸送达最需要它的部位,确保最佳吸收效果。
3、抗氧化、抗炎:姜黄能行气破瘀,通经止痛,是很好的消炎杀菌的抗炎作用,改善泌尿生殖系统症状。
4、调节新陈代谢:产品配方补充维生素、各种矿物质元素,提高更年期妇女的代谢活力,提高机体免疫能力,促进人体营养成分吸收,缓解因更年期带来的营养缺失。
本发明还要求保护上述组合物的制备方法,包括如下步骤:
1)原料混合:将大豆异黄酮、南极磷虾油、姜黄油、稀释剂、维生素与矿物质按重量配比混合搅拌均匀;
2)高压均质:将步骤1)所得混料加入到均化器中匀浆,保温,所得到的液体转移至高压匀质机,于100~150MPa下进行匀质,循环处理,得均质内容物;
3)制备胶囊囊体:将甘油、色素和纯净水注入溶胶罐内,加热搅拌均匀后加入食用明胶,继续搅拌均匀后真空脱泡,制得胶囊囊体;
4)将步骤2)中所得的匀质内容物与步骤3)所得的胶囊囊体经过压丸、成型、洗丸、干燥,制得软胶囊。
进一步,步骤3)中所述的色素为柠檬黄、亮蓝、焦糖色、日落黄、胭脂红、二氧化钛、棕氧化铁、黄氧化铁的一种或多种的混合物。
进一步,步骤3)中所述甘油、纯净水和食用明胶的质量比为(0.2~1):(0.3~0.6):(0.4~1)。
进一步,步骤2)中保温的温度为55~60℃,保温时间15~25min。
进一步,步骤2)中高压匀质的时间为15~25min。
本发明的有益效果是:本发明通过大豆异黄酮、南极磷虾油、姜黄油、稀释剂、维生素和矿物质进行复配,并通过制丸技术,获得的软胶囊组合物产品对缓解女性更年期综合症方面具有很好的效果,且效果显著,无其它副作用。
具体实施方式
以下结合实例对本发明的原理和特征进行描述,所举实例只用于解释本发明,并非用于限定本发明的范围。
实施例1:
一种缓解女性更年期综合症的组合物,包括如下组分:大豆异黄酮5份、南极磷虾油15份、姜黄油15份、亚麻籽油35份、维生素E 2份、葡萄糖酸锌5份。
上述组合物的制备方法如下:
1)原料混合:将大豆异黄酮、南极磷虾油、姜黄油、亚麻籽油、维生素E与葡萄糖酸锌按重量配比混合搅拌均匀;
2)高压均质:将步骤1)所得混料加入到均化器中匀浆35min,于60℃下保温25min,所得到的液体转移至高压匀质机,于150MPa下进行匀质25min,循环处理,得均质内容物;
3)制备胶囊囊体:将甘油、色素和纯净水注入溶胶罐内,加热至75℃搅拌均匀后加入食用明胶,继续搅拌30min后真空脱泡,制得胶囊囊体,甘油、纯净水、食用明胶的质量比为1:0.6:1;
4)将步骤2)中所得的匀质内容物与步骤3)所得的胶囊囊体经过压丸、成型、洗丸、干燥,制得软胶囊0.60g/粒。
实施例2:
一种缓解女性更年期综合症的组合物,包括如下组分:大豆异黄酮15份、南极磷虾油20份、姜黄油5份、月见草油30份、维生素B 1份、卟啉铁3份。
上述组合物的制备方法如下:
1)原料混合:将大豆异黄酮、南极磷虾油、姜黄油、月见草油、维生素B与卟啉铁按重量配比混合搅拌均匀;
2)高压均质:将步骤1)所得混料加入到均化器中匀浆25min,于50℃下保温15min,所得到的液体转移至高压匀质机,于100MPa下进行匀质20min,循环处理,得均质内容物;
3)制备胶囊囊体:将甘油、色素和纯净水注入溶胶罐内,加热至75℃搅拌均匀后加入食用明胶,继续搅拌30min后真空脱泡,制得胶囊囊体,甘油、纯净水、食用明胶的质量比为0.2:0.6:0.6;
4)将步骤2)中所得的匀质内容物与步骤3)所得的胶囊囊体经过压丸、成型、洗丸、干燥,制得软胶囊0.60g/粒。
实施例3:
一种缓解女性更年期综合症的组合物,包括如下组分:大豆异黄酮20份、南极磷虾油5份、姜黄油20份、米糠油50份、维生素D 5份、碳酸钙1份。
上述组合物的制备方法如下:
1)原料混合:将大豆异黄酮、南极磷虾油、姜黄油、米糠油、维生素D与碳酸钙按重量配比混合搅拌均匀;
2)高压均质:将步骤1)所得混料加入到均化器中匀浆30min,于60℃下保温20min,所得到的液体转移至高压匀质机,于125MPa下进行匀质20min,循环处理,得均质内容物;
3)制备胶囊囊体:将甘油、色素和纯净水注入溶胶罐内,加热至75℃搅拌均匀后加入食用明胶,继续搅拌25min后真空脱泡,制得胶囊囊体,甘油、纯净水、食用明胶的质量比为0.5:0.5:1;
4)将步骤2)中所得的匀质内容物与步骤3)所得的胶囊囊体经过压丸、成型、洗丸、干燥,制得软胶囊0.60g/粒。
为了验证本发明提供的组合物在缓解更年期综合症方面的技术效果,我们使用实施例1所得产品进行了如下动物实验:
1、实验动物及方法
取14~16月龄雌性大鼠,体重360~420g,进行2周的阴道脱落细胞涂片检查,观察有无发情期改变。选取无发情周期大鼠50只作更年期大鼠实验用。将更年期大鼠随机分为5组,每组10鼠,分别为更年期组、雌激素组、组合物高、中、低剂量组(2.4g/kg、1.2g/kg、0.6g/kg)。另取3月龄正常早性大鼠10只作为青年鼠组(正常对照组)。更年期组、正常对照组给予等体积蒸馏水,激素组每周一次灌胃给予尼尔雌醇1mg/kg,其余时间给等体积蒸馏水。每天灌胃给药一次,连续4周,停药后次日,戊巴比妥钠麻醉动物,取血、脏器进行实验,测定血清中雌二醇(E2)、促黄体生成素(LH)、促卵泡生成素(FSH)。
2、实验结果
表1组合物对更年期大鼠生殖内分泌激素的作用
表2组合物对更年期脏器系数的影响
通过动物实验结果可以看出,组合物连续灌胃给药4周,可明显降低更年期大鼠血清促性腺激素FSH含量,对血清E2含量有显著增加作用,表明其对阴虚内热大鼠紊乱的生殖内分泌系统有明显的双向调节作用,使更年期烦躁不安、失眠等症状得以缓解。同时可明显增加模型大鼠子宫重量,表明其对“更年期”大鼠可直接或间接作用于卵巢、垂体,以调节生殖内分泌功能,缓解下丘脑.垂体.性腺轴的衰退,能改善围绝经期不良症状的功能。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种缓解女性更年期综合症的组合物,其特征在于,按重量份计,包括如下组分:大豆异黄酮5-20份、南极磷虾油5-20份、姜黄油5-20份、稀释剂30-50份、维生素1-5份、矿物质1-5份。
2.根据权利要求1所述的组合物,其特征在于,所述稀释剂为亚麻籽油、红花油、月见草油、山茶油、米糠油、玉米油中的一种或多种的混合物。
3.根据权利要求1所述的组合物,其特征在于,所述维生素为维生素E、维生素C、维生素D、B族维生素中的一种或多种的混合物。
4.根据权利要求1所述的组合物,其特征在于,所述矿物质为葡萄糖酸锌、硫酸锌、硫酸亚铁、卟啉铁、乳酸亚铁、碳酸钙的一种或多种的混合物。
5.一种如权利要求1-4中任一项所述的组合物的制备方法,其特征在于,包括如下步骤:
1)原料混合:将大豆异黄酮、南极磷虾油、姜黄油、稀释剂、维生素与矿物质按重量配比混合搅拌均匀;
2)高压均质:将步骤1)所得混料加入到均化器中匀浆,保温,所得到的液体转移至高压匀质机,于100~150MPa下进行匀质,循环处理,得均质内容物;
3)制备胶囊囊体:将甘油、色素和纯净水注入溶胶罐内,加热搅拌均匀后加入食用明胶,继续搅拌均匀后真空脱泡,制得胶囊囊体;
4)将步骤2)中所得的匀质内容物与步骤3)所得的胶囊囊体经过压丸、成型、洗丸、干燥,制得软胶囊。
6.根据权利要求5所述的组合物的制备方法,其特征在于,步骤3)中所述的色素为柠檬黄、亮蓝、焦糖色、日落黄、胭脂红、二氧化钛、棕氧化铁、黄氧化铁的一种或多种的混合物。
7.根据权利要求5所述的组合物的制备方法,其特征在于,步骤3)中所述甘油、纯净水和食用明胶的质量比为(0.2~1):(0.3~0.6):(0.4~1)。
8.根据权利要求5所述的组合物的制备方法,其特征在于,步骤2)中保温的温度为55~60℃,保温时间15~25min。
9.根据权利要求5所述的组合物的制备方法,其特征在于,步骤2)中高压匀质的时间为15~25min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610966018.6A CN106509890A (zh) | 2016-10-31 | 2016-10-31 | 一种缓解女性更年期综合症的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610966018.6A CN106509890A (zh) | 2016-10-31 | 2016-10-31 | 一种缓解女性更年期综合症的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106509890A true CN106509890A (zh) | 2017-03-22 |
Family
ID=58326451
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610966018.6A Pending CN106509890A (zh) | 2016-10-31 | 2016-10-31 | 一种缓解女性更年期综合症的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106509890A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110074211A (zh) * | 2019-06-05 | 2019-08-02 | 济南极源生物科技有限公司 | 一种含有南极磷虾油的产品的制备方法及制备得到的产品 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799541A (zh) * | 2004-12-30 | 2006-07-12 | 天津中新药业集团股份有限公司 | 大豆异黄酮软胶囊及其制备工艺 |
CN103446529A (zh) * | 2013-07-30 | 2013-12-18 | 魏光春 | 一种用于女性调经养巢、延缓更年期的配制酒的生产工艺 |
CN104664401A (zh) * | 2013-11-30 | 2015-06-03 | 烟台巨先药业有限公司 | 一种大豆异黄酮维e软胶囊 |
CN105381221A (zh) * | 2015-12-02 | 2016-03-09 | 桂龙药业(安徽)有限公司 | 一种含有磷虾油增强免疫力的颗粒剂 |
CN105661509A (zh) * | 2016-01-18 | 2016-06-15 | 烟台新时代健康产业有限公司 | 一种保护骨健康的磷虾油软胶囊及其制备方法和应用 |
-
2016
- 2016-10-31 CN CN201610966018.6A patent/CN106509890A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1799541A (zh) * | 2004-12-30 | 2006-07-12 | 天津中新药业集团股份有限公司 | 大豆异黄酮软胶囊及其制备工艺 |
CN103446529A (zh) * | 2013-07-30 | 2013-12-18 | 魏光春 | 一种用于女性调经养巢、延缓更年期的配制酒的生产工艺 |
CN104664401A (zh) * | 2013-11-30 | 2015-06-03 | 烟台巨先药业有限公司 | 一种大豆异黄酮维e软胶囊 |
CN105381221A (zh) * | 2015-12-02 | 2016-03-09 | 桂龙药业(安徽)有限公司 | 一种含有磷虾油增强免疫力的颗粒剂 |
CN105661509A (zh) * | 2016-01-18 | 2016-06-15 | 烟台新时代健康产业有限公司 | 一种保护骨健康的磷虾油软胶囊及其制备方法和应用 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110074211A (zh) * | 2019-06-05 | 2019-08-02 | 济南极源生物科技有限公司 | 一种含有南极磷虾油的产品的制备方法及制备得到的产品 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101496862B (zh) | 一种治疗不孕的中药组合物及其制备方法 | |
CN101375968A (zh) | 一种中药组合物及其制备方法和用途 | |
CN105816617A (zh) | 一种治疗肥胖型多囊卵巢综合征的中药组合物 | |
CN1806840B (zh) | 一种中药复方制剂及其制备方法 | |
CN109602892A (zh) | 一种快速补肾的牡蛎多肽组合物及其制备方法 | |
CN106578537A (zh) | 一种防治产后炎症的哺乳母猪预混合饲料及其制备方法 | |
CN101152281A (zh) | 一种复方玫瑰精油软胶囊及其制备方法 | |
CN105146228A (zh) | 用于母猪保胎的中药复方制剂及其制备方法 | |
CN101579020A (zh) | 不含饱和脂肪酸的食用油 | |
CN109259219A (zh) | 一种鹿鞭蜜丸及其制备方法 | |
CN101041007A (zh) | 一种补肾生精的中药及其制备方法 | |
CN106509890A (zh) | 一种缓解女性更年期综合症的组合物及其制备方法 | |
CN107136281A (zh) | 一种用于改善女性肾功能的昆布虫草压片糖果及其制备方法 | |
CN106306473A (zh) | 一种怀孕期母猪饲料及其制备方法 | |
Mayo | A natural approach to menopause | |
CN106729283A (zh) | 一种用于家畜催情促孕的中药组合物及其制备方法 | |
CN106036880A (zh) | 一种缓解痛经的组合物及其应用和由其制成的健康食品 | |
CN104906526A (zh) | 一种用于卵巢早衰的中药制剂及其制备方法 | |
CN1480204A (zh) | 一种治疗妇女不孕症的中药制剂 | |
CN104645297A (zh) | 一种温宫助孕的中药组合物及其制剂制备方法 | |
CN116139133B (zh) | 改善早发性卵巢功能不全的药物组合物及其应用 | |
CN1330325C (zh) | 预防、治疗骨质疏松症的药物及其制备方法 | |
CN103191373B (zh) | 一种治疗肾虚型乳腺增生的中药及制备方法 | |
KR20170105280A (ko) | 전립선과 방광 및 성기능 향상을 위한 건강기능식품 제조방법 및 그 조성물 | |
CN105106652A (zh) | 改善妇女产后乳汁不通的鲤鱼粥 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170322 |
|
RJ01 | Rejection of invention patent application after publication |